0

Hijacking DNA Methyltransferase Transition State Analogues to Produce Chemical Scaffolds for PRMT Inhibitors

Ludovic Halby, Nils Marechal, Dany Pechalrieu, Vincent Cura, Don-Marc Franchini, Céline Faux, Fréderic Alby, Nathalie Troffer-Charlier, Srikanth Kudithipudi, Albert Jeltsch, Wahiba Aouadi, Etienne Decroly, etc.

Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):20170072.

PMID: 29685976

Abstract:

DNA, RNA and histone methylation is implicated in various human diseases such as cancer or viral infections, playing a major role in cell process regulation, especially in modulation of gene expression. Here we developed a convergent synthetic pathway starting from a protected bromomethylcytosine derivative to synthesize transition state analogues of the DNA methyltransferases. This approach led to seven 5-methylcytosine-adenosine compounds that were, surprisingly, inactive against hDNMT1, hDNMT3Acat, TRDMT1 and other RNA human and viral methyltransferases. Interestingly, compound 4 and its derivative 2 showed an inhibitory activity against PRMT4 in the micromolar range. Crystal structures showed that compound 4 binds to the PRMT4 active site, displacing strongly the S-adenosyl-l-methionine cofactor, occupying its binding site, and interacting with the arginine substrate site through the cytosine moiety that probes the space filled by a substrate peptide methylation intermediate. Furthermore, the binding of the compounds induces important structural switches. These findings open new routes for the conception of new potent PRMT4 inhibitors based on the 5-methylcytosine-adenosine scaffold.This article is part of a discussion meeting issue 'Frontiers in epigenetic chemical biology'.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR42416084 PRMT4 Active human PRMT4 Active human Price
qrcode